GEN0101 will be administered four times per two weeks and then washed out for two weeks. This one cycle will be repeated twice. GEN0101 will be given at a dose of 30,000mNAU for each injection. If dos

2 trials

Sponsors

Osaka University, Osaka University Hospital, Center for respiratory

Conditions

Castration resistant prostate cancerChemotheapy-resistant Malignant Pleural Mesothelioma

Phase 1

Phase 1 dose-escalation, safety / tolerability and preliminary efficacy study of intratumoral and subcutaneous administration of GEN0101 in patients with recurrence of castration resistant prostate cancer

Active, not recruitingJPRN-UMIN000017092

Osaka UniversityCastration resistant prostate cancer

Start: 2015-06-12Target: 12Updated: 2026-06-29

Phase 1 Dose-escalation, Safety / Tolerability and Preliminary Efficacy Study of Intratumoral and Subcutaneous Administration of GEN0101 in Patients with Chemotheapy-resistant Malignant Pleural Mesothelioma (Phase I).

RecruitingJPRN-UMIN000019345

Osaka University Hospital, Center for respiratoryChemotheapy-resistant Malignant Pleural Mesothelioma

Start: 2015-11-15Target: 12Updated: 2026-06-29

Related Papers

Dose-escalation, tolerability, and efficacy of intratumoral and subcutaneous injection of hemagglutinating virus of Japan envelope (HVJ-E) against chemotherapy-resistant malignant pleural mesothelioma: a clinical trial

Cancer Immunology Immunotherapy2024-10-033 citations

Intratumoral and s.c. injection of inactivated hemagglutinating virus of Japan envelope (GEN0101) in metastatic castration‐resistant prostate cancer

Cancer Science2020-02-2918 citations

Intratumoral and subcutaneous injection of HVJ-E (GEN0101) for metastatic castration-resistant prostate cancer: Open-label, phase I, dose escalation study.

Journal of Clinical Oncology2019-05-201 citations

Phase I/II clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E in castration-resistant prostate cancer patients.

2017-05-1214 citations